This is the authors' abstract. We don't add key points for this paper.
PTPN22 is a cytosolic tyrosine phosphatase expressed in immune cells that negatively regulates T cell receptor (TCR) signaling and implicated in autoimmune diseases through a common (R620W) variant. The molecular mechanisms by which PTPN22 modulates TCR activation remain incompletely understood. Here we show that upon T cell activation, PTPN22 forms delayed clusters at TCR microclusters (MCs) alongside Csk, STS-1 and PSTPIP, constituting a feedback inhibitory complex. Using imaging analyses, MS, and knockout mouse models, we demonstrate that this complex functions as a delayed negative regulation of TCR signaling, and that autoimmune-associated PTPN22 (R620W) mutant exhibits reduced binding to Csk and STS-1, impairing complex formation. Consequently, T cells expressing the mutant display enhanced cytokine production and immune responses. These findings reveal cooperative inhibitory mechanism involving PTPN22 and its partners that modulates T cell activation, providing insights into how PTPN22 variants contribute to autoimmune disease susceptibility.
No takes yet. Share an insight, caveat, or question.
Hashimoto et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: